期刊文献+

多重位点特异性PCR检测骨髓增殖性疾病五种JAK2基因突变 被引量:7

Multiplex sequence-specific PCR detection for simultaneous screening of 5 types of JAK2 mutations in myeloproliferative diseases
原文传递
导出
摘要 目的建立一种同时检测多种朋也基因突变的多重位点特异性PCR方法,并探讨其对骨髓增殖性疾病(MPD)的临床应用价值。方法建立同时检测JAK2 V617F突变和JAK2 exon12中K539L(包括2种基因突变)、N542-E543del和E543-D544del突变的多重位点特异性PCR方法。对115例MPD患者进行检测,包括61例真性红细胞增多症(PV)患者、43例原发性血小板增多症(ET)患者和11例原发性骨髓纤维化(MF)患者。结果建立的PCR方法可以同时检测上述5种朋怨基因突变,可以检测出1%的JAK2 V617F突变型等位基因,对其他几种突变可检测出0.1%的突变型等位基因。在61例PV患者中,检测出JAK2 V617F突变56例JAK2 exon12突变3例;在43例ET患者中,检测出JAK2 V617F突变27例,未检测到JAK2 exon12突变;在11例MF患者中,检测到JAK2 V617F突变6例,未检测到JAK2 V617F突变。3例JAK2 exon12突变的患者临床表现为血红蛋白增多,内源性红系集落生成阳性,但白细胞和血小板增多不明显,不伴脾肿大。结论多重位点特异性PCR方法检测灵敏度高,可联合检测5种JAK2基因突变,能有效提高突变检出率。 Objective To develop a multiplex sequence-specific PCR assay for simultaneous screening of 5 types of JAK2 mutations and investigate its clinical application value. Methods Multiplex sequence-specific PCR assay for simultaneous screening of JAK2 V617F, K539L ( include 2 types of gene mutations ), N542-E543del and E543-D544del mutations were developed. 115 patients with myeloproliferative diseases (MPD) including 61 polycythemia vera (PV) cases, 43 essential thrombocythemia (ET) cases and 11 primary myelofibrosis (MF) cases were analyzed. Results The assay can screen the 5 types of JAK2 mutations efficiently. The detection sensitivity is 1% for JAK2 V617F mutation and 0. 1% for the other mutations. JAK2 V617F mutation and JAK2 exon12 mutation were detected in 56 and 3 of the 61 PV samples, respectively. 27 of the 43 ET samples and 6 of the 11 MF samples were JAK2 V617F positive, but no JAK2 exon12 mutation was found in both groups. The 3 cases carrying JAK2 exon12 mutation had the clinical feature of erythrocytosis and erythropoietin-independent erythroid colony formation but without apparent leukocytosis, thrombocytosis and splenectasis. Conclusion The assay can simultaneously screen 5 types of JAK2 mutations with high sensitivity and thus lead to an increased detection rate.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2009年第1期30-34,共5页 Chinese Journal of Laboratory Medicine
基金 国家科技部国际科技合作重大项目(2006DFB31430) 国家自然科学基金资助项目(30470939)
关键词 骨髓增殖性疾病 JANUS激酶2 突变 聚合酶链反应 Myeloproliferative disorders Janus kinase 2 Mutation Polymerase chain reaction
  • 相关文献

参考文献17

  • 1James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 2005, 434 : 1144-1148.
  • 2Zhao R, Xing S, Li Z, et al. Identification of an Acquired JAK2 Mutation in Polyeythemia Vera. J Biol Chem, 2005, 280:22788- 22792.
  • 3Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 2005, 365:1054-1061.
  • 4Vannuechi AM, Pancrazzi A, Bogani C, et al. A quantitative assay for JAK2 (V617F) mutation in myeloprohferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia, 2006, 20 : 1055-1060.
  • 5Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood, 2006, 108 : 1865-1867.
  • 6Cazzola M. Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosis. Haematologica, 2007, 92:1585-1589.
  • 7Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms : the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia, 2008, 22 : 14-22.
  • 8Ormazabal C, Hurtado C, Aranaz P, et al. Low frequency of JAK2 exon 12 mutations in classic and atypical CMPDs. Leuk Res, 2008, 32 : 1485-1487.
  • 9Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 2002, 100:2292-2302.
  • 10刘红星,童春荣,蔡鹏,顾江英,林跃辉,张英,滕文,王赫,朱平.真性红细胞增多症和原发性血小板增多症JAK2 V617F基因纯合突变克隆分析[J].首都医科大学学报,2008,29(2):113-117. 被引量:13

二级参考文献22

  • 1赵峻峰,朱平,张英,杜金伟,刘红星,刘静,庄昕,邱志祥.实时定量聚合酶链反应在急性早幼粒细胞白血病融合基因检测中的临床应用[J].中华检验医学杂志,2006,29(5):424-427. 被引量:5
  • 2朱平.骨髓增殖性疾病JAK2基因突变的临床意义[J].中华医学杂志,2006,86(32):2243-2245. 被引量:14
  • 3James C, Ugo V, Le Couedic J P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera [ J ]. Nature, 2005,434 : 1144- 1148.
  • 4Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera [J]. J Biol Chem, 2005,280:22788- 22792.
  • 5Baxter E J, Scott L M, Campbell P J, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [ J ]. Lancet, 2005,365 : 1054- 1061.
  • 6Guido Finazzi and Tiziano Barbui. How I treat patients with polycythemia vera [ J ]. Blood, 2007,109 : 5104- 5111.
  • 7Vannucchi A M, Pancrazzi A, Bogani C, et al. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis [ J ]. Leukemia, 2006,20 : 1055- 1060.
  • 8Vardiman J W, Harris N L. The World Health Organization ( WHO ) classification of the myeloid neoplasms [ J ]. Blood, 2002,100:2292- 2302.
  • 9Dupont S, Masse A, James C, et al. The JAK2 617V > F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera[ J ]. Blood, 2007,110:1013- 1021.
  • 10Lippert E, Boissinot M, Kralovics R, et al. The JAK2- V617F mutation is frequently present at diagnosis in patients with essential thromboeythemia and polyeythemia vera [J]. Blood, 2006,108 : 1865- 1867.

共引文献12

同被引文献137

引证文献7

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部